

Immunity

2020 May 19

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

Authors

Álvaro Teijeira, Saray Garasa,
María Gato, ..., Pedro Berraondo,
Jose L. Perez-Gracia, Ignacio Melero

Journal Club 03.05.2021

Neutrophils and Cancer

- Pro-tumorigenic
 - Pro-angiogenic
 - Immunosuppressive
- Presence of tumor-infiltrating neutrophils = poor prognosis
- **G**ranulocytic **M**yeloid-**D**erived **S**uppressor **C**ells (GR-MDSCs)
 - Subset of neutrophil-like cells
 - T-cell suppressive functions
 - Expanded in cancer-bearing hosts

CXCR1 and CXCR2

- Expressed on Neutrophils & GR-MDSCs
- CXCR1 → CXCL6 and CXCL8
- CXCR2 → CXCL1 – CXCL7 chemokines; sharing ELR motif
- ELR⁺ CXCL chemokines recruit myeloid cells to tumors (mostly Neutros)

- CXCL1, CXCL2, CXCL8 produced by cancer cells
- CXCR1 / CXCR2 inhibition = promoted T cell response against tumors due to limited GR-MDSC or Neutrophil infiltration

Do Neutrophil Chemoattractants induce NETosis in Neutrophils and GR-MDSCs?


Treatment of

- Healthy donor Neutrophils
- GR-MDSCs from cancer patients
- Mouse GR-MDSCs from mice bearing 4T1 tumors

with


- Chemoattractants
- +/- Pertussis Toxin (Ptx) as G_i subunit inhibitor
- +/- Reparixin (Rep) as specific allosteric CXCR1 and CXCR2 inhibitor

Fig.1 Neutrophil Chemoattractants induce NETosis in Neutrophils and GR-MDSCs



- Reduced NETosis upon G_i subunit inhibition (PTX)
 - Chemokine-induced NETosis acting via CXCR1 / CXCR2 \rightarrow reduced upon PTX treatment
- Reparixin reduced CXCR1 / CXCR2 dependent NET induction

Fig.1 Neutrophil Chemoattractants induce NETosis in Neutrophils and GR-MDSCs



- Reduced NETosis upon G_i subunit inhibition (PTX)
- Chemokine-induced NETosis acting via CXCR1 / CXCR2 \rightarrow reduced upon PTX treatment
- Reparixin reduced CXCR1 / CXCR2 dependent NET induction
- similar results in GR-MDSCs
- from cancer patients as seen
- in Neutrophils
- Mouse GR-MDSCs from 4T1
- tumor bearing mice showed similar activation pattern as human Neutros or GR-MDSCs

Do Tumor-derived Factors Induce NETosis in Neutrophils and GR-MDSCs by Activating CXCR1 and CXCR2 Receptors?

Treatment of



- Healthy donor Neutrophils
- GR-MDSCs from cancer patients

with

- Culture supernatant of five different primary melanoma cell lines and one colon carcinoma cell line (HT29)

Generation of 3D tumor spheroids with Neutrophil co-culture

Fig.2 Tumor-derived Factors Induce NETosis in Neutrophils and GR-MDSCs by Activating CXCR1 and CXCR2 Receptors



- a. CM^{hi} = potent NET inducer (independent of cancer cell line)
both, Ptx and Rep = potent inhibitors
- b. Anti-CXCR1 antibody could abolish NET-inducing capacity of cancer cell line CM^{hi}
- c. similar results in GR-MDSCs upon Reparixin induced CXCR inhibition






Fig.2 Tumor-derived Factors Induce NETosis in Neutrophils and GR-MDSCs by Activating CXCR1 and CXCR2 Receptors



Co-culture of 3D spheroids with Neutrophils induced NETosis

NETosis could be prevented by Reparixin treatment

HT29 Spheroids in Co-culture with Human Neutrophils


HT29/ CMRA
Neutrophils/ Cell Tracker Deep Red
NETs/ Sytox Green

10 hours video. 450x accelerated

To visualize the presence of NETs inside tumors

- 4T1 bearing mice
 - treated for 20h with either Ptx or Reparixin
- citH3 & Ly6G staining in tumor tissue samples


Fig. 3 Tumors Induce NETosis by activation of CXCR1 and CXCR2 Chemokine Receptors



Can human tumors induce NETosis?

- Subcutaneous xenograft of HT29 tumor cells in Rag2^{-/-} IL2rg^{-/-} mice (lacking T-cells and NK-cells)
- Human pre-stained Neutrophils were injected intratumorally
+/- Ptx
+/- Reparixin
- 24h later → tumors were excised and analyzed
- 5min prior euthanasia: mice received SYTOX green systemically


Fig. 3 Tumors Induce NETosis by activation of CXCR1 and CXCR2 Chemokine Receptors



Is cytotoxicity impaired by NETs shielding cancer cells?

- 3D spheroids grown for 3 days
- Neutrophils added to spheroids
+IL-8 / +PMA to induce NETosis
or as control: +IL-8 / +PMA, + DNaseI
- Co-culture of effector cytotoxic lymphocytes with NET-covered tumor cells
 - IL-15 activated NK cells
 - CD3 plus CD28 activated CD8⁺ T cells

Fig. 4 NETs Inhibit Immune Cell Cytotoxicity by Impeding Contact with Tumor Cells



Higher numbers of surviving tumor cells in presence of NETs independent of NET-stimulus or effector lymphocytes







Fig. 4 NETs Inhibit Immune Cell Cytotoxicity by Impeding Contact with Tumor Cells



>80% of tumor cells survived in cytotoxic lymphocyte co-cultures WHEN covered in NETs





No T cell bi-specific engager (EpCAM-CD3) = no cytotoxicity



Do NETs shield tumor cells from contact with cytotoxic immune cells?



- Time-lapse confocal microscopy (same co-cultures as before)
- NETs generated over chemotaxis transwells
to see whether they directly impair CD8⁺ T cell migration

Fig. 4 NETs Inhibit Immune Cell Cytotoxicity by Impeding Contact with Tumor Cells





less lymphocyte-tumor cell contacts in presence of NETs

Fig. 4 NETs Inhibit Immune Cell Cytotoxicity by Impeding Contact with Tumor Cells



Less CD8⁺ T cell migration over chemotaxis transwells towards CCL5 in presence of NETs

Restoration of chemotaxis by DNase I treatment




Do NETs influence immune-cell control of tumor metastasis?


- Lung metastasis mouse model in mice bearing 4T1 bilateral tumors
 - WT BALB/C
 - Rag1 ^{-/-} (lack T cells)
 - Rag2 ^{-/-} IL2rg ^{-/-} (lack T cells and NK cells)
- Intravenous injection of 4T1 mCherry tagged tumor cells

Fig. 5 NETs Limit Immune Response and Checkpoint-Based Immunotherapy against 4T1 Tumors

B



C




DNase1 treatment and PAD4 inhibition could sign. reduce the number of lung mCherry⁺ 4T1 micrometastases 24h post IV injection in **WT** and **Rag1^{-/-}** but **not in Rag2^{-/-} IL2rg^{-/-}** mice

Selective NK cell depletion showed similar results

→ **Indication that NK cells are capable of controlling early stages of metastases**

Fig. 5 NETs Limit Immune Response and Checkpoint-Based Immunotherapy against 4T1 Tumors



IP treatment with PAD4 inhibitor minimally decreased tumor progression


Combination of PAD4 inhibitor and anti-PD-1 plus anti-CTLA-4 checkpoint inhibitors showed sign. reduction in tumor progression

PAD4-immune checkpoint tumor suppression is CD8⁺ T cell dependent

Intravital microscopy of NETs impairing NK and T cell –tumor contact

- IVM of liver and subcutaneous tumors located in ear dermis
- Mice with subcutaneous Lewis-Lung-Carcinoma (LLC) tumors received fluorescent labelled LLCs intrasplenically
- Similar experiment but in recipient mice with GFP labelled NK cells or RFP labelled T cells

Fig. 6 NETs Impair Cytotoxic Cell Contact with Tumor Cells in the Metastatic Intravascular Niche




IVM simultaneous comparison of CTLs in NET-rich and NET-lacking areas

- 4T1 mCherry tumors implanted into ears of mice carrying 4T1 tumors in the flank
- Due to uneven SYTOX (=NETs) distribution → simultaneous comparison of CTL behaviour possible
- Injection of B16OVA-H2BmCherry tumors in ears of mice adoptively transferred fluorescently labelled OT-I CD8⁺ T cells (recognizing OVA)
- Direct injection with human pre-stained NETs

Fig. 7 NETs Impair Cytotoxic Cell Contact with Tumor Cells in Subcutaneous Tumors

Uneven NETs distribution; not necessarily coating tumor cells

A



B








Fig. 7 NETs Impair Cytotoxic Cell Contact with Tumor Cells in Subcutaneous Tumors

NETs surrounding tumor cells prevented OTI cells from contacting tumor cells

NET-rich areas showed impaired T cell-tumor cell contact




B16 OVA H2BmCh/NET(Sytox Green)/OTI Cells



LLC GFP tumor cells (green) implanted in the ear of hCD2RFP mice (T-cells, Red) in the presence of NE fluorescent substrate to visualize NETs(blue)

Discussion

- Tumor-derived CXCR1 and CXCR2 ligands trigger NETosis in human and mouse Neutrophils and GR-MDSCs
- NETs protect tumor cells from cytotoxic T lymphocytes and NK cytotoxicity



Discussion

- Inhibition of NETosis, via PAD4 inhibition, sensitizes tumors to immune checkpoint therapy (PD-1+CTLA-4)
- NETs impair contact of immune cells with tumor cells in mice

